HOERSHOLM, Denmark, Dec. 22 /PRNewswire/ -- Summary: Pharmexa has acquired a portfolio of intellectual property rights within the field of immunotherapy from Vectron Therapeutics, a German biotech company in liquidation.
The technologies cover novel targeted liposomal delivery systems and recombinant antibody-like proteins known as single chain diabodies. The rights were acquired from Vectron Therapeutics AG, a German biotech company currently in liquidation and include both issued and pending patent applications. Liposomes are a well-known effective delivery system that can be formulated with either AutoVaca Protein or AutoVaca DNA pharmaccines. Diabodies are small antibody-like fragments that have many capabilities, including passive immunotherapy.
Pharmexa's CEO Jakob Schmidt says: "In the mid- to long-term, these technologies could potentially complement our immunotherapy platform in a number of interesting ways, while right now representing a very inexpensive opportunity for us. The acquisition of Vectron's patents supports our strategy to secure for ourselves the best possible position in the field of immunotherapy, in terms of products, technology and intellectual property."
The acquisition has no effect on Pharmexa's expectations to the financial result for 2004 and 2005.
Hoersholm, December 22, 2004
Chief Executive Officer
Jakob Schmidt, Chief Executive Officer, telephone +45 4516 2525
Note to editors: Pharmexa A/S is a leading company in the field of active immunotherapy for the treatment of serious chronic diseases. Pharmexa's proprietary AutoVac(TM) technology platform is broadly applicable, but the company has focused its resources on a number of cancer forms and chronic inflammatory diseases, with research and development programs targeted towards breast cancer, rheumatoid arthritis and bone degeneration. Collaborative agreements include Schering-Plough, H. Lundbeck and Bavarian Nordic.
CONTACT: Jakob Schmidt, Chief Executive Officer, telephone,+45-4516-2525